<DOC>
	<DOCNO>NCT03052634</DOCNO>
	<brief_summary>A significance , safety pharmacokinetic open-label multicentric Phase Ib/II Study RC48-ADC Administered Intravenously Subjects With HER2-Positive Advanced Breast Cancer</brief_summary>
	<brief_title>RC48-ADC Administered Intravenously Subjects With HER2-Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Signed informed consent form ; Aged 1870 years； Eastern Cooperative Oncology Group ( ECOG ) physical condition 0 1； Life expectancy great 12 weeks； Confirmed histology cytology，the patient HER2 positive , locally advanced metastatic breast cancer，and perform effect standard therapy ( disease progression treatment treatment free remission ) intolerant standard treatment accept standard treatment . Patients locally advance metastatic advanced breast cancer diagnose pathology refractory standard care therapy , standard care therapy available histology standard care therapy , standard care therapy available； Documented Human epidermal growth factor receptor 2 ( HER2 ) positive measure either immunohistochemistry ( IHC 2+ fluorescence situ hybridization ( FISH ) immunohistochemistry ( score , 3+ ) ; Patients measurable appreciable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Adequate organ function define follow criterion : （1）absolute neutrophil count ( ANC ) &gt; = 1.5 x 10 ( 9 ) /L ; ( 2 ) platelet &gt; =100*10 ( 9 ) /L ; ( 3 ) Total serum bilirubin &lt; =1.5*ULN ; ( 4 ) serum aspartate transaminase ( AST）and serum alanine transaminase ( ALT ) &lt; =2.5*upper limit normal ( ULN ) , AST ALT &lt; =5*ULN liver function abnormality due underlying malignancy ; ( 5 ) Serum creatinine clearance rate &gt; = 45 mL/min ; ( 6 ) international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) must less equal 1.5 time upper limit normal range ( ULN ) ; Women childbearing potential men must agree use adequate contraception ( e.g. , condom , implant , injectables , combine oral contraceptive , intrauterine device , complete sexual abstinence , sterilize partner ) prior study entry period therapy 30 day last dose study drug . Left ventricular ejection fraction ( LVEF ) &gt; = 50 % assessed echocardiogram . Current pregnancy lactation . The patient receive anticancer therapy within 4 week study drug treatment ; , include chemotherapy , radiotherapy , surgery hormone therapy , molecular target therapy ( include trastuzumab ) , use Trastuzumab emtansine ( TDM1 ) clinical study participate clinical trial drug analogue . The patient third interstitial fluid ( large number pleural effusion ascites ) clinical symptom control drainage method ; Received Palliative radiation therapy bone metastasis within 2 week study drug treatment ; Unresolved toxicities prior anticancer therapy , define resolved Common Terminology Criteria Adverse Event ( CTCAE , version 4 ) , grade less equal to1 , level dictate inclusion/exclusion criterion exception alopecia ; Participated clinical drug study within 4 week ; know hypersensitivity delay hypersensitivity component RC48ADC similar drug ; active infection clinical significance accord researcher 's judgment , Known history immune deficiency , include HIVpositive know acquire congenital immunodeficiency , organ transplantation ; Unwilling unable participate require study evaluation procedure . Serious complication diabetes , interstitial pneumonia , pulmonary fibrosis , hypertension Acute lung disease ; variety factor affect medication intake absorption unable swallow , chronic diarrhea intestinal obstruction ; uncontrolled primary metastatic tumor brain ; Patients receive systemic steroid therapy long time ( Patients receive systemic steroid therapy short time stop drug 2 week could enrol ) ; Preexisting peripheral neuropathy ≥ grade 2 ; History nerve psychiatric disorder ; Cardiovascular disease problem includingAcute myocardial infarction， unstable angina , myocardial infarction , stroke , transient ischemic attack New York Heart Association ( NYHA ) grade 2 ( include 2 ) congestive heart failure within last 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>